ARTEMIDE-01: safety and preliminary efficacy of rilvegostomig
PD-1 and TIGIT play a significant role in the immunosuppressive response of T cells in cancer. Rilvegostomig, a bispecific IgG1 antibody that targets both PD-1 and TIGIT, has been developed in a humanized form. In murine models, it has shown promising activity when compared to both anti-PD-1 and anti-PD-1/-TIGIT combination therapies. During the ASCO 2023 conference, Professor Dr Kristoffer Rohrberg presented data from the ARTEMIDE-01 study, which consisted of a dose escalation phase (Part A) and an expansion cohort (Part B) involving patients with advanced non-small cell lung cancer (NSCLC) who had received previous treatment with checkpoint inhibitors and had a PD-L1 tumour proportion score of ≥1%. The primary endpoints of this open-label, multicenter study included assessing the safety, tolerability, dose-limiting toxicities, and preliminary efficacy of rilvegostomig.
With the educational support of:
